Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Non-Current Deffered Revenue (2023 - 2025)

Coya Therapeutics' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 10.74% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, down 10.74%, while the annual FY2024 figure was $945447.0, 64.52% up from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $1.1 million at Coya Therapeutics, up from $641158.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.2 million in Q3 2024 and bottomed at $574685.0 in Q4 2023.
  • The 3-year median for Non-Current Deffered Revenue is $775542.5 (2024), against an average of $838440.6.
  • The largest annual shift saw Non-Current Deffered Revenue surged 64.52% in 2024 before it fell 25.16% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $574685.0 in 2023, then soared by 64.52% to $945447.0 in 2024, then rose by 15.42% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Non-Current Deffered Revenue are $1.1 million (Q3 2025), $641158.0 (Q2 2025), and $694435.0 (Q1 2025).